Study of AMG531(Romiplostim) in Patients With Aplastic Anemia

Summary

To evaluate the hematological responses based on the response assessment criteria when AMG531 is subcutaneous (SC)-administered with anti-human thymocyte immunoglobulin (ATG) + ciclosporin A (CsA) therapy for 6 months in patients with aplastic anemia (AA) who were previously untreated with immunosuppressive therapy.

Timeline

Start

2019-04-25

Primary completion

2020-11-05

Completion

2021-05-26

Drugs

Indications